2020
Evaluation of the incidence of acute nausea and vomiting after administration of an amino acid solution containing only arginine and lysine with lutetium Lu-177 dotatate.
Alonzo N, Seyer M, Kim E, Keshavarzi R, Yee K, Kunz P. Evaluation of the incidence of acute nausea and vomiting after administration of an amino acid solution containing only arginine and lysine with lutetium Lu-177 dotatate. Journal Of Clinical Oncology 2020, 38: 12113-12113. DOI: 10.1200/jco.2020.38.15_suppl.12113.Peer-Reviewed Original ResearchLu-177 DOTATATEAA infusionAmino acid solutionRates of nauseaPercentage of patientsRetrospective chart reviewGastroenteropancreatic neuroendocrine tumorsAcute nauseaSecondary endpointsAdult patientsChart reviewNeuroendocrine tumorsNormal salinePatientsInfusion timeAA solutionIncidenceDOTATATEInfusionHistorical incidenceAmino acids 10NauseaVomitingAdministrationEssential AA
2017
Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome.
Weickert M, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle J, Caplin M, Bergsland E, Kunz P, Anthony L, Grande E, Oberg K, Warner R, Lombard-Bohas C, Welin S, Fleming R, Kittur A, Arnold K, Yang Q, Kulke M. Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. Journal Of Clinical Oncology 2017, 35: e15692-e15692. DOI: 10.1200/jco.2017.35.15_suppl.e15692.Peer-Reviewed Original ResearchMetastatic neuroendocrine tumorsCarcinoid syndromeWeek 12Neuroendocrine tumorsTelotristat ethylWeight gainWeight lossWeight changeDouble-blind treatment periodUncontrolled carcinoid syndromeBowel movement frequencyBody mass indexCochrane-Armitage testStatistical analysis planBM frequencyAdverse eventsAnalogue therapyDiarrhea severityPerformance statusMass indexBaseline ageTreatment periodPatientsReduced survivalIncidence